Article Information
History
- December 2, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Klara Acs1,*,
- Juho J. Miettinen2,*,
- Philipp Sergeev2,*,
- Tobias Heckel3,
- Yumei Diao1,
- Kristina Witt-Mulder1,
- Marcus Thureson1,
- Thorsten Bischler3,
- Maiju-Emilia Huppunen2,
- Jakob Obermüller1,
- Umair Munawar4,
- Ana Slipicevic1,İ,
- Ralf C. Bargou4,
- Fredrik Lehmann1,İİ,
- Stefan Svensson Gelius1,
- Stefan Norin1,
- Fredrik Schjesvold5,
- Pieter Sonneveld6,
- Thorsten Stühmer4 and
- Caroline A. Heckman2,†
- 1Oncopeptides AB, Stockholm, Sweden
- 2Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland
- 3Core Unit Systems Medicine, University of Würzburg, Würzburg, Germany
- 4Comprehensive Cancer Center Mainfranken, Würzburg, Germany
- 5Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway
- 6Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
- ↵†Corresponding author. caroline.heckman{at}helsinki.fi
↵* K.A., J.J.M and P.S. contributed equally to this study.
Posted December 02, 2024.
Efficacy of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma and Mutated or Deleted TP53
